THROMBOCYTOPENIA AS A RISK FACTOR FOR RETINOPATHY OF PREMATURITY.
Angiogenesis Inhibitors
/ therapeutic use
Bevacizumab
/ therapeutic use
Birth Weight
Case-Control Studies
Female
Gestational Age
Humans
Infant, Newborn
Infant, Premature
Intravitreal Injections
Laser Coagulation
Male
Retinopathy of Prematurity
/ diagnosis
Retrospective Studies
Risk Factors
Thrombocytopenia
/ diagnosis
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
26
1
2018
medline:
25
4
2020
entrez:
26
1
2018
Statut:
ppublish
Résumé
To study the association between thrombocytopenia and retinopathy of prematurity (ROP). The case-control study was conducted on preterm newborns with ROP between January 2011 and January 2014, retrospectively. The patients were assigned into two groups: Cases required intervention and controls developed no or Stage I ROP. Eighty-one premature infants with Type I ROP were enrolled to the study with a mean gestational age of 27.6 ± 2.1 (range: 24-32) weeks and birth weight of 993 ± 292 (range: 560-1,930) g. Mean follow-up time was 38.3 ± 2.7 weeks (min: 32 and max: 46 weeks). Cases were individually matched to a set of controls (1:1 ratio). Thrombocytopenia (<150.000/mm) was seen in 58 (71.6%) of the cases with Type I ROP, whereas only 17 (21%) of the controls had thrombocytopenia (P < 0.001). Logistic regression analysis showed that bronchopulmonary dysplasia and thrombocytopenia were significantly associated with Type I ROP (relative risk [95% confidence interval]: 4.19 [1.47-12] and 6.69 [2.83-15.9], respectively). The thrombocytopenia ratio (P = 0.073), thrombocytopenia 1 week before intervention (P = 0.076) and platelet transfusion ratio (P = 0.062) tended to be higher in Zone I ROP compared with Zone II ROP. In our study, there was a significant association between thrombocytopenia and Type I ROP.
Identifiants
pubmed: 29370028
doi: 10.1097/IAE.0000000000002028
doi:
Substances chimiques
Angiogenesis Inhibitors
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM